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efﬁcacy than latanoprost in controlling the IOP for patients with
ocular hypertension or glaucoma.
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OBJECTIVE: This study aimed at estimating the potential public
health impact of Retaane 15mg (anecortave acetate suspen-
sion)in age-related macular degeneration. METHODS: Based on
clinical trial results and literature, a Markov model was built to
compare anecortave acetate to best supportive care (BSC) during
the lifetime of ARMD patients. Patients entering the model were
75 years of age with a new diagnosis of wet ARMD in one eye.
This model took into account the efﬁcacy of anecortave acetate
to slow deterioration and delay visual disability, the probability
for a patient to develop the disease in the fellow eye, and mor-
tality. Results of the model were expressed in terms of duration
of low vision (with blindness in one eye) and blindness in both
eyes. Health consequences of blindness and low vision were esti-
mated for depression and hip fractures as well as for institu-
tionalization. Duration of the model was 25 years and the cycle
length was 1 month. The fellow eye could be affected in 30% of
the patients at ﬁve years. Premature mortality associated with
blindness and low vision was estimated. RESULTS: Anecortave
acetate decreased the number of prevalent blind cases by 20%
and the average time with blindness by 30%. Depression preva-
lent cases were decreased by 21% and those with hip fracture
by 10%. The number of patients who were institutionalized was
decreased by 27%. Decrease in life expectancy due to premature
mortality associated with blindness and low vision could be esti-
mated at 17% in the BSC group and 15.5% in the anecortave
acetate group. Life expectancy was increased by 3 months.
CONCLUSION: Anecortave acetate presents important and
favorable potential public health outcomes in patients with wet
ARMD. According to the model it could reduce the rates of
depression, hip fractures and institutionalization, and increase
life expectancy compared with BSC.
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OBJECTIVE: To estimate the number of treatable eyes with wet
sub-foveal ARMD in France. METHODS: Surveys documenting
wet ARMD incidence rate were searched in the literature. Direct
standardization according to age and gender was performed
using INSEE demographic data. Projection at year 2025 was per-
formed using OECD data. A 75 years old cohort was simulated
using a 7-states Markov model. Mean treatment duration of
New Chemical Entity is not known today and therefore was
ﬁxed arbitrarily at 2 years. The probability to develop ARMD
in the fellow eye was ﬁxed at 30% at 5 years. Monthly death
incidence rate was modeled from INSEE mortality tables. The
time horizon of the model was 25 years and the cycle length 
one month. Sensitivity analyses were performed. RESULTS: 3
surveys were identiﬁed. The Rotterdam Study, the only one per-
formed in the EU, was chosen as the best proxy for France. In
2005, 30,192 citizens will develop ARMD in the ﬁrst eye; of
those 17,585 will be wet and 13,805 will be wet sub-foveal
(Olsen, 2004). Taking into account the fellow eye, mortality and
the base case scenario treatment duration, the number of wet
sub-foveal treatable eyes would be 37,019. Treatment duration
is the most sensitive parameter of the model. Number of eyes
would be 18,899, 53,204, 67,535, and 80,162 for a treatment
duration of 1, 3, 4 and 5 years, respectively. The number of treat-
able eyes will increase by 7.1% if probability to develop the
disease in the second eye is 40%, and decrease by -9.0% if it is
20%. A 2% yearly increase is expected till 2025 due to popula-
tion aging and the 1950s’ baby-boom. CONCLUSION: Accord-
ing to our model, the number of sub-foveal wet ARMD treatable
eyes would be 37,019, in France. Average treatment duration
was the most sensitive parameter.
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OBJECTIVE: LASEK is one of the current surgical technique to
correct refractive errors of the eye, such as myopia, hyperopia,
and astigmatism. In this method, the corneal epithelial ﬂap is
lifted then replaced after laser ablation of the subepithelial
cornea. The hinged ﬂap is created by epithelial marking and
exposure of the marking ethyl alcohol (20%) for 5 seconds.
METHODS: LASIK (Laser in Situ Keratomileusis) is a surgical
procedure to correct myopia by corneal stroma subtraction. It
involves the use of a microkeratome to make a lamellar dissec-
tion of the cornea creating a ﬂap with intact corneal epithelium.
After the ﬂap is lifted, the underlying midstroma is reshaped with
an excimer laser and the ﬂap is returned to its original position.
We have detected eighteen cases where the treatment of patients
that had been subjected to LASEK with polyvinyl alcohol artiﬁ-
cial tear drops provoked eye adverse effects. Toxicogenic kerati-
tis, partial epithelium detachment, and allergic and toxicogenic
conjunctivitis were observed. These adverse effects disappeared
upon discontinuing tear drops administration and reappeared
after their reintroduction. We used the Naranjo et al. algorithm
to conﬁrm the cause-effect relationship. RESULTS: All cases
were conﬁrmed as deﬁnitive. CONCLUSION: We have not
observed any case of eye adverse effect in patients subjected to
LASIK caused by polyvinyl alcohol tear drops.
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OBJECTIVE: To develop a health-economic assessment for
Macugen, a new treatment for age-related macular degeneration
(AMD). A comprehensive model compares Macugen (pegap-
tanib sodium), indicated for all patients with neovascular AMD,
relative to the existing photodynamic therapy with Visudyne
(verteporﬁn). METHODS: A Markov framework was used to
model the lifetime movement of an AMD cohort through ﬁve
